Ionis Pharmaceuticals, the RNA-targeted therapeutics specialist, will use Aro Biotherapeutics’ Centyrin technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs).
The companies will collaborate to create unique ASO-Centyrin conjugates that are designed to achieve tissue specific, therapeutically effective gene knockdown in extra-hepatic tissues with systemic administration.
Aro will be responsible for Centyrin discovery and will collaborate with Ionis to create lead ASO-Centyrin drug conjugates for further development.
Ionis, on the other hand, will be responsible for development and will have global commercialisation rights for each ASO-Centyrin drug conjugate. The parties will also collaborate on additional discovery programs.
Aro will receive an upfront cash payment, funding to support R&D efforts, and payments associated with the achievement of specific development and commercial milestones, up to $1.4 billion. In addition, Aro will receive royalties on net sales.